Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561521 · ClinicalTrials.gov registry record · Phase 3
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
A Phase 3 study of Allergic Conjunctivitis, sponsored by Akorn.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT01561521 is a Phase 3 study of Allergic Conjunctivitis that has completed, run by Akorn. The registered enrollment target is 90 participants, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01561521, a Phase 3 study of Allergic Conjunctivitis, has completed, sponsored by Akorn.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
Conditions Studied
Interventions
- DRUG AKF-1
Study Locations (1)
Massachusetts
- Andover Eye Associates - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561521
The ClinicalTrials.gov registry entry for NCT01561521 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target (31% lower). The listed sponsor is Akorn, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which AKF-1 is the first listed.
NCT01561521 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01561521 about?
NCT01561521 is a clinical study titled "An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis". The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
What is the current status of trial NCT01561521?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2012-03. Estimated completion is 2012-04.
What conditions does trial NCT01561521 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01561521?
The interventions under investigation include: AKF-1 (DRUG).
Who is sponsoring clinical trial NCT01561521?
This trial is sponsored by Akorn, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01561521 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy
RECRUITING · Phase 3
-
Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis
COMPLETED · Phase 3
-
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
COMPLETED · Phase 3
-
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
COMPLETED · Phase 3
-
Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution
COMPLETED · Phase 3
-
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.